Ranbaxy Malaysia Sdn Bhd, a wholly owned subsidiary of Ranbaxy Laboratories Limited has received approval from the Government of Malaysia for setting up a Greenfield manufacturing facility in Malaysia as an EPP (Entry Point Project). This will be Ranbaxy’s second manufacturing facility in Malaysia.

The announcement was made by Dato' Sri Mohd Najib bin Tun Abdul Razak, the Prime Minister of Malaysia, at a ceremony held in Putrajaya, Malaysia.

Ranbaxy will be investing around RM 125 million (US$ 40 million) in this project that will provide employment to over 200 people.

On the approval of the new manufacturing facility, Arun Sawhney, CEO & managing director, Ranbaxy said, “Ranbaxy has been providing high quality, affordable generic pharmaceuticals to the healthcare system of Malaysia for the last 30 years thereby helping the Government to bring down healthcare costs. The setting up of a new manufacturing facility reinforces our commitment to the Malaysian market. In addition to serving the local market the facility will also export products to markets like ASEAN, Middle East, Europe, Sri Lanka, China and other select countries.”

The new facility would manufacture dosage forms including tablets and capsules primarily in the cardiovascular, anti diabetic, anti-infective and gastrointestinal segments. Ranbaxy’s total output in Malaysia will be increased from one billion doses per annum to three billion doses per annum when the new facility is fully operational.

Commenting on the occasion, Jeyabalan Thangarajah, managing director, Ranbaxy Malaysia Sdn. Bhd. said, “We are pleased that the Government of Malaysia has approved Ranbaxy’s investment in a new manufacturing facility and the project has been accorded Entry Point Project (EPP) status under the Government Economic Transformational Programme (ETP).”

Ranbaxy Malaysia Sdn Bhd recently celebrated 30 years of successful operations in Malaysia. Earlier in the year the company was awarded the 2012 Frost & Sullivan Malaysia Excellence Award for being adjudged the Malaysian Pharmaceutical Company of the Year in the Generics Drug Category.

Ranbaxy Malaysia Sdn Bhd (RMSB) is a joint venture company of Ranbaxy Laboratories Limited, India and Malaysian shareholders. RMSB is one of the major generic companies in this market providing medicines in the cardiovascular, CNS, anti-infective, gastroenterology and anti-viral therapeutic segments.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.